An Underused Lifesaver for COVID-19 Patients

The Colorado Clinical Translational Sciences Institute is spreading the word about monoclonal antibody treatment for COVID-19.

Adit Ginde, MD, and the Colorado Clinical Translational Sciences Institute team are spreading the word about monoclonal antibody treatment for COVID-19.

As the COVID-19 pandemic continues to lurk in many communities, aided by vaccine hesitancy and the emergence of disease mutations like the Delta variant, physicians are still looking for effective ways to treat those who test positive for the virus.

The Colorado Clinical and Translational Sciences Institute (CCTSI) on the University of Colorado Anschutz Medical Campus is part of an effort to increase awareness and uptake of monoclonal antibody treatments for COVID-19. The treatment has an emergency use authorization from the FDA, and researchers at CCTSI have a grant from the National Institutes of Health to aid in its adoption.

“We want to have effective treatments for patients if and when they do get sick,” says Adit Ginde, MD, professor of emergency medicine at the University of Colorado School of Medicine and principal investigator on the study. “Patients are still getting sick, they’re still getting hospitalized, and they’re still dying. My concern is that’s going to increase with the Delta variant.”

CTSA Program In Action Goals
Goal 2: Engage Patients and Communities in Every Phase of the Translational Process
Goal 3: Promote the Integration of Special and Underserved Populations in Translational Research Across the Human Lifespan
Goal 4: Innovate Processes to Increase the Quality and Efficiency of Translational Research, Particularly of Multisite Trials